USFDA issues warning letter to Intas Pharma for Sanand plant

Intas Pharmaceuticals has been criticised by the USFDA for multiple manufacturing faults, including deficiencies in its quality control systems at its Sanand-based manufacturing plant. The US health regulator issued a warning letter saying the faults mean the company's drug products are adulterated.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hoQscO0
via IFTTT

0 comments:

Post a Comment